Editing Aspirin (section)

===Other uses===
Aspirin is a first-line treatment for the fever and joint-pain symptoms of [[rheumatic fever|acute rheumatic fever]]. The therapy often lasts for one to two weeks, and is rarely indicated for longer periods. After fever and pain have subsided, the aspirin is no longer necessary, since it does not decrease the incidence of heart complications and residual rheumatic heart disease.<ref name=NHFA>{{cite web |url=http://www.racgp.org.au/Content/NavigationMenu/ClinicalResources/RACGPGuidelines/DiagnosisandmanagementofacuterheumaticfeverandrheumaticheartdiseaseinAustralia/NHFA-CSANZ_ARF_RHD_2006.pdf |archive-url=https://web.archive.org/web/20080726052030/http://www.racgp.org.au/Content/NavigationMenu/ClinicalResources/RACGPGuidelines/DiagnosisandmanagementofacuterheumaticfeverandrheumaticheartdiseaseinAustralia/NHFA-CSANZ_ARF_RHD_2006.pdf |archive-date=26 July 2008 |title=Diagnosis and management of acute rheumatic fever and rheumatic heart disease in Australia. An evidence-based review |author=[[National Heart Foundation of Australia]] (RF/RHD guideline development working group) and the Cardiac Society of Australia and New Zealand |year=2006 |publisher=National Heart Foundation of Australia |pages=33–37}}</ref><ref>{{cite journal | vauthors = Saxena A, Kumar RK, Gera RP, Radhakrishnan S, Mishra S, Ahmed Z | title = Consensus guidelines on pediatric acute rheumatic fever and rheumatic heart disease | journal = Indian Pediatrics | volume = 45 | issue = 7 | pages = 565–73 | date = July 2008 | pmid = 18695275 }}</ref> [[Naproxen]] has been shown to be as effective as aspirin and less toxic, but due to the limited clinical experience, naproxen is recommended only as a second-line treatment.<ref name=NHFA/><ref>{{cite journal | vauthors = Hashkes PJ, Tauber T, Somekh E, Brik R, Barash J, Mukamel M, Harel L, Lorber A, Berkovitch M, Uziel Y | title = Naproxen as an alternative to aspirin for the treatment of arthritis of rheumatic fever: a randomized trial | journal = The Journal of Pediatrics | volume = 143 | issue = 3 | pages = 399–401 | date = September 2003 | pmid = 14517527 | doi = 10.1067/S0022-3476(03)00388-3 }}</ref>

Along with rheumatic fever, [[Kawasaki disease]] remains one of the few indications for aspirin use in children<ref>{{cite journal | vauthors = Rowley AH, Shulman ST | title = Pathogenesis and management of Kawasaki disease | journal = Expert Review of Anti-Infective Therapy | volume = 8 | issue = 2 | pages = 197–203 | date = February 2010 | pmid = 20109049 | pmc = 2845298 | doi = 10.1586/eri.09.109 }}</ref> in spite of a lack of high quality evidence for its effectiveness.<ref>{{cite journal | vauthors = Baumer JH, Love SJ, Gupta A, Haines LC, Maconochie I, Dua JS | title = Salicylate for the treatment of Kawasaki disease in children | journal = The Cochrane Database of Systematic Reviews | issue = 4 | pages = CD004175 | date = October 2006 | volume = 2010 | pmid = 17054199 | doi = 10.1002/14651858.CD004175.pub2 | pmc = 8765111 }}</ref>

Low-dose aspirin supplementation has moderate benefits when used for prevention of [[pre-eclampsia]].<ref>{{cite journal | vauthors = Duley L, Meher S, Hunter KE, Seidler AL, Askie LM | title = Antiplatelet agents for preventing pre-eclampsia and its complications | journal = The Cochrane Database of Systematic Reviews | volume = 2019 | issue = 10 | date = October 2019 | pmid = 31684684 | pmc = 6820858 | doi = 10.1002/14651858.CD004659.pub3 }}</ref><ref name=Roberge_2012>{{cite journal | vauthors = Roberge S, Villa P, Nicolaides K, Giguère Y, Vainio M, Bakthi A, Ebrashy A, Bujold E | title = Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis | journal = Fetal Diagnosis and Therapy | volume = 31 | issue = 3 | pages = 141–6 | year = 2012 | pmid = 22441437 | doi = 10.1159/000336662 | s2cid = 26372982 | doi-access = free | title-link = doi }}</ref> This benefit is greater when started in early pregnancy.<ref>{{cite journal | vauthors = Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E | title = The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis | journal = American Journal of Obstetrics and Gynecology | volume = 216 | issue = 2 | pages = 110–120.e6 | date = February 2017 | pmid = 27640943 | doi = 10.1016/j.ajog.2016.09.076 | s2cid = 3079979 }}</ref>

Aspirin has also demonstrated [[Treatment of cancer|anti-tumoral]] effects, via inhibition of the [[PTTG1]] gene, which is often overexpressed in tumors.<ref>{{cite journal|title=Aspirin Mediates Its Antitumoral Effect Through Inhibiting PTTG1 in Pituitary Adenoma|doi=10.1210/clinem/dgac496|doi-access=free|journal=[[The Journal of Clinical Endocrinology and Metabolism]]|vauthors=Szabó B, Németh K, Mészáros K, Krokker L, Likó I, Saskői E, Németh K, Szabó PT, Szücs N, Czirják S, Szalóki G, Patócs A, Butz H|date=5 September 2022|volume=107|issue=11|pages=3066–3079|pmid=36059148 |pmc=9681612 }}</ref>